MDWD MediWound

MediWound to Present at Upcoming Investor Conferences

MediWound to Present at Upcoming Investor Conferences

MediWound to Present at Upcoming Investor Conferences

YAVNE, Israel, February 17, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that its management team will present at the following upcoming investor conferences:

Oppenheimer 36th Annual Healthcare Life Sciences Conference

Date: Thursday, February 26, 2026

Time: 10:40 a.m. ET

Location: Virtual

Webcast:

TD Cowen 46th Annual Health Care Conference

Date: Monday, March 2, 2026

Time: 1:10 p.m. ET

Location: Boston Marriott Copley Place, Boston, MA

Webcast:

A live webcast and replay of each presentation will be accessible through the section of the Investor Relations area of MediWound’s website.

About MediWound

MediWound Ltd. (Nasdaq: MDWD) is a global biotechnology company pioneering enzymatic, non-surgical therapies for tissue repair. The company’s FDA-approved biologic, NexoBrid®, is indicated for the enzymatic removal of eschar in thermal burns and is marketed in the United States, European Union, Japan, and additional international markets. MediWound’s late-stage pipeline product, EscharEx®, is an investigational therapy for the debridement of chronic wounds, with potential to become a new standard of care in wound management.

For more information, visit and follow us on and .



MediWound Contacts:        







Hani Luxenburg        

Chief Financial Officer

MediWound Ltd.



Daniel Ferry

Managing Director

LifeSci Advisors, LLC







EN
17/02/2026

Underlying

MDWDMediWound

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MediWound

 PRESS RELEASE
Free
MDWD MEDIWOUND

MediWound to Report Fourth Quarter and Full Year 2025 Financial Result...

MediWound to Report Fourth Quarter and Full Year 2025 Financial Results MediWound to Report Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast Scheduled for Thursday, March 5th at 8:30 a.m. Eastern Time YAVNE, Israel, February 19, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2025 on Thursday, March 5, 2026. Following the release, MediWound’s management will host a conference ca...

February 19, 2026 1 EN
 PRESS RELEASE
Free
MDWD MEDIWOUND

MediWound to Present at Upcoming Investor Conferences

MediWound to Present at Upcoming Investor Conferences MediWound to Present at Upcoming Investor Conferences YAVNE, Israel, February 17, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that its management team will present at the following upcoming investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences Conference Date: Thursday, February 26, 2026 Time: 10:40 a.m. ET Location: Virtual Webcast: TD Cowen 46th Annual Health Care Conference Date: Monday, March 2, 2026 Time: 1:10 p.m. ET ...

February 17, 2026 1 EN
 PRESS RELEASE
Free
MDWD MEDIWOUND

MediWound Provides Corporate Update and Financial Outlook Ahead of the...

MediWound Provides Corporate Update and Financial Outlook Ahead of the J.P. Morgan Healthcare Conference MediWound Provides Corporate Update and Financial Outlook Ahead of the J.P. Morgan Healthcare Conference Interim assessment and enrollment completion for the EscharEx® VALUE Phase III trial in venous leg ulcers (VLUs) expected by year-end 2026; expansion to diabetic foot ulcers (DFUs) and pressure ulcers (PUs) anticipated in 2026 Expanded NexoBrid® manufacturing facility fully operational; regulatory approvals targeted for 2026 $17 million in 2025 revenue; financial guidance updated...

January 12, 2026 1 EN
 PRESS RELEASE
Free
MDWD MEDIWOUND

MediWound Reports New Clinical Data Demonstrating NexoBrid®’s Effectiv...

MediWound Reports New Clinical Data Demonstrating NexoBrid®’s Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast Injuries MediWound Reports New Clinical Data Demonstrating NexoBrid®’s Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast Injuries Prospective clinical data show NexoBrid® removes embedded particles in friction and blast wounds, reducing pigmented wound surface by >90% Traumatic tattoos form when dirt, metal, or explosive residue becomes permanently embedded in the skin; findings support further evaluation in acute trauma settings YA...

December 10, 2025 1 EN
 PRESS RELEASE
Free
MDWD MEDIWOUND

MediWound Reports Third Quarter 2025 Financial Results and Provides Co...

MediWound Reports Third Quarter 2025 Financial Results and Provides Corporate Update Ongoing Enrollment Continues in VALUE Phase III Trial of EscharEx® in Venous Leg Ulcers Commissioning Completed for Expanded NexoBrid® Facility; Full Operational Capacity Expected by Year-End 2025 Balance Sheet Strengthened with $30 Million Equity Financing Third Quarter 2025 Revenue of $5.4 Million, Up 23% Year-over-Year Conference Call Today, November 20, 2025, at 8:30 a.m. Eastern Time YAVNE, Israel, Nov. 20, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generati...

November 20, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch